Drug Names
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial
While the Phase III trial didn't meet the primary overall survival endpoint in PD-L1-positive patients, BMS will continue to track other endpoints.
ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential
Premium
Researchers urged other oncologists to look for ALK rearrangements in GI patients and try to get them on ALK inhibitors through trials or compassionate use programs.